1. Home
  2. Labeler Index
  3. Gland Pharma Limited
  4. 68083-446
  5. NDC Package Code: 68083-446-01 Thiotepa

NDC Package 68083-446-01 Thiotepa

Injection, Powder, Lyophilized, For Solution Intracavitary; Intravenous; Intravesical - View Billable Units, 11-Digit Format, RxNorm

Table of Contents

    1. Package Information
    2. Frequently Asked Questions

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
68083-446-01
Package Description:
1 VIAL in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL
Product Code:
68083-446
Proprietary Name:
Thiotepa
Non-Proprietary Name:
Thiotepa
Substance Name:
Thiotepa
Usage Information:
Thiotepa is used to treat cancer. It works by slowing or stopping the growth of cancer cells. Thiotepa is often given into the bladder to treat bladder cancer. Thiotepa is also used with other medications to prevent rejection of a stem cell transplant.
11-Digit NDC Billing Format:
68083044601
NDC to RxNorm Crosswalk:
Product Type:
Human Prescription Drug
Labeler Name:
Gland Pharma Limited
Dosage Form:
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route(s):
  • Intracavitary - Administration within a non-pathologic cavity, such as that of the cervix, uterus, or penis, or such as that which is formed as the result of a wound.
  • Intravenous - Administration within or into a vein or veins.
  • Intravesical - Administration within the bladder.
Active Ingredient(s):
THIOTEPA 15 mg/1
Pharmacologic Class(es):
Sample Package:
No
FDA Application Number:
ANDA214222
Marketing Category:
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date:
03-08-2021
Listing Expiration Date:
12-31-2026
Exclude Flag:
N
Code Structure:

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

Frequently Asked Questions

What is NDC 68083-446-01?

The NDC Packaged Code 68083-446-01 is assigned to a package of 1 vial in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial of Thiotepa, a human prescription drug labeled by Gland Pharma Limited. The product's dosage form is injection, powder, lyophilized, for solution and is administered via intracavitary; intravenous; intravesical form.

Is NDC 68083-446 included in the NDC Directory?

Yes, Thiotepa with product code 68083-446 is active and included in the NDC Directory. The product was first marketed by Gland Pharma Limited on March 08, 2021 and its listing in the NDC Directory is set to expire on December 31, 2026 if the product is not updated or renewed by the manufacturer.

What is the 11-digit format for NDC 68083-446-01?

The 11-digit format is 68083044601. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
5-3-268083-446-015-4-268083-0446-01